Impact of aspirin on the prognosis in patients with coronary spasm without significant atherosclerotic stenosis.

[1]  K. Sakamoto,et al.  Impact of Statin Therapy on Clinical Outcome in Patients With Coronary Spasm , 2016, Journal of the American Heart Association.

[2]  Y. Izumiya,et al.  Determinants of Myocardial Lactate Production During Acetylcholine Provocation Test in Patients With Coronary Spasm , 2015, Journal of the American Heart Association.

[3]  Y. Izumiya,et al.  Acetylcholine-Provoked Coronary Spasm at Site of Significant Organic Stenosis Predicts Poor Prognosis in Patients With Coronary Vasospastic Angina. , 2015, Journal of the American College of Cardiology.

[4]  T. Akasaka,et al.  OCT-Defined Morphological Characteristics of Coronary Artery Spasm Sites in Vasospastic Angina. , 2015, JACC. Cardiovascular imaging.

[5]  R. Dreyer,et al.  Systematic Review of Patients Presenting With Suspected Myocardial Infarction and Nonobstructive Coronary Arteries , 2015, Circulation.

[6]  K. Shimada,et al.  Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. , 2014, JAMA.

[7]  R. Virmani,et al.  Mechanisms of Plaque Formation and Rupture , 2014 .

[8]  S. Hokimoto,et al.  Coronary Vasomotor Response to Intracoronary Acetylcholine Injection, Clinical Features, and Long‐term Prognosis in 873 Consecutive Patients With Coronary Spasm: Analysis of a Single‐Center Study Over 20 Years , 2013, Journal of the American Heart Association.

[9]  Erling Falk,et al.  Update on acute coronary syndromes: the pathologists' view. , 2013, European heart journal.

[10]  M. Wintermark,et al.  Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2013, Stroke.

[11]  苅尾 七臣,et al.  ガイドライン解説 AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease : 2011 update , 2012 .

[12]  N. Sattar,et al.  Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. , 2012, Archives of internal medicine.

[13]  Xiantao Song,et al.  Coronary spasm, a pathogenic trigger of vulnerable plaque rupture. , 2011, Chinese medical journal.

[14]  John Spertus,et al.  AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. , 2011, Circulation.

[15]  Harlan M Krumholz,et al.  ACC/AHA clinical performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures on ST-Elevation and Non-ST-El , 2006, Journal of the American College of Cardiology.

[16]  K. Okumura,et al.  Soluble P-selectin is released into the coronary circulation after coronary spasm. , 1995, Circulation.

[17]  K. Okumura,et al.  Fibrinopeptide A is released into the coronary circulation after coronary spasm. , 1990, Circulation.

[18]  H. Yasue,et al.  Coronary Arterial Spasm in Ischemic Heart Disease and Its Pathogenesis: A Review , 1983, Circulation research.

[19]  R. Frye,et al.  A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. , 1975, Circulation.

[20]  Guidelines for diagnosis and treatment of patients with vasospastic angina (Coronary Spastic Angina) (JCS 2013). , 2014, Circulation journal : official journal of the Japanese Circulation Society.

[21]  JCSJointWorkingGroup.  Guidelines for Diagnosis and Treatment of Patients With Vasospastic Angina (Coronary Spastic Angina) (JCS 2013):– Digest Version – , 2014 .

[22]  Hani Jneid,et al.  2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Forc , 2012, Journal of the American College of Cardiology.

[23]  T. Morimoto,et al.  Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients With Type 2 Diabetes , 2012 .

[24]  R. Collins,et al.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. , 2009, Lancet.

[25]  Jane A. Linderbaum,et al.  ACC/AHA clinical performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures on ST-Elevation and Non-ST-El , 2006, Circulation.

[26]  A. Trubetskoi.  [Coronary spasm]. , 1989, Kardiologiia.